Switching from calcitonin gene-related peptide monoclonal antibody monthly to fremanezumab quarterly based on the patient's preferred dosing schedule

We have read with great interest the paper by Ihara et al. [1] entitled “Switching between anti-calcitonin gene-related peptide monoclonal antibodies: A comparison of monthly and quarterly dosing”. The authors retrospectively reviewed the clinical data of 15 patients with migraine who initially responded well to monthly galcanezumab but later switched to quarterly f remanezumab (n = 13) to reduce the number of hospital visits for monthly galcanezumab dosing or to monthly fremanezumab (n = 2) to avoid side effects related to galcanezumab.
Source: Journal of the Neurological Sciences - Category: Neurology Authors: Source Type: research